A293780 Share Price Performance
₩0
-7160.00 (-100.00%)
Price ₩0
Share Pricen/a
Is AptaBio Therapeutics (KOSDAQ:293780) Weighed On By Its Debt Load?
Nov 13
AptaBio Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A293780 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
AptaBio Therapeutics Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -581.85
- 34.84%
- -442.04%
- 9.0%
About A293780
- Founded
- 2009
- Employees
- 32
- CEO
- WebsiteView website
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells. The company was founded in 2009 and is based in Yongin-si, South Korea.
